己酮可可碱抗大鼠肝纤维化的实验研究  

Experimental Study on Pentoxifylline against Liver Fibrosis in Rat

作　　者：张瑞红[1] 钱绍诚[2] 吕洪敏[2] 张文[2] 

机构地区：[1]天津市天和医院,300050 [2]天津市第三中心医院

出　　处：《天津医药》2002年第4期225-227,I003,共4页Tianjin Medical Journal

摘　　要：目的:已酮可可碱是一种甲基黄嘌呤血管扩张剂,观察其对综合因素诱导的大鼠肝纤维化的治疗效果,探讨其作用机理、方法:实验采用CCl4及高脂低胆碱及酒精饮食诱导,形成大鼠肝纤维化模型,然后分别给予口服已酮可可碱、秋水仙碱及蒸馏水对照治疗10周。治疗前后测定血ALT,纤维化指标IV型胶原,细胞因子肿瘤坏死因子-α的浓度,同时作肝脏病理检查。结果:口服已酮可可碱大鼠血清ALT、IV型胶原、肿瘤坏死因子-α浓度均低于对照组(P<0.05),病理结果表明已酮可可碱治疗后肝纤维化分级低于对照组(P<0.05),染色显示其胶原面积百分比下降,低于对照组(P<0.05)。结论:已酮可可碱能有效治疗及预防大鼠肝纤维化,是具有临床抗纤维化治疗潜力的药物。Objective: To study the effect of pentoxifylline on the treatment of liver fibrosis in rat models and its mechanism. Methods: Hepatic fibrosis models in rat were performed by administering CCl4 and dietetic factory, and were divided into three groups treated with pentoxifylline, colchicine, and placebo by 10 weeks respectively. Before and after the treatment,serum level of ALT, TNF-α, and type IV collagen were tested, and changes in histological were observed. Results: Theserum levels of ALT and type IV collagen decreased in model treated by pentoxifylline and colchicine, and the levels in thistwo groups were lower than that in control group (P<0.05). Strum TNF-α in rat with pentoxifylline was lower than thatin other groups. In the liver section treated with pentoxifylline and colchicine, the liver fibrosis score and percentage of collagen decreased and were lower than that in control group (P<0.05). Conclusion: Pentoxifylline can effectively suppressand treat hepatic fibrosis in rat.

关 键 词：肝硬化 药物疗法 治疗 己酮可可碱 大鼠 肝纤维化 实验研究 

分 类 号：R575.2[医药卫生—消化系统]